 |
Consilium Strategic Communications is handling the merger of Oculis and European Biotech Acquisition Corp. in a SPAC deal valued in the $220M range. The combined entity will trade on the NASDAQ.
Switzerland-based Oculis is a biopharma company focused on developing treatments to save sight and improve eye care.
Riad Sherif, Oculis CEO, said proceeds from the EBAC transaction will be used to accelerate development of drugs in its pipeline.
EBAC has screened over 100 European biotech companies.
CEO Eduardo Bravo called Oculis a prime example of what his company wants to invest in.
He said Oculis has “great innovation, a well thought-out strategy and an experienced management team to bring promising therapies to market for patients suffering from eye disease.”
Oculis has product candidates to treat macular edema, dry eye disease and nero-retina indicators such as glaucoma.
Consilium Strategic Communications, which works in the healthcare PR and IR space, has Amber Fennell, Matthew Cole and David Daley working the Oculis deal.
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
Uber’s Mike Lucarelli is moving to NXP Semiconductors as senior VP-investor relations.
